BioNTech SE (BNTX) Cash & Equivalents (2018 - 2025)

BioNTech SE has reported Cash & Equivalents for 8 years, with the latest figure at $8.9 billion in Q4 2025.

• Quarterly Cash & Equivalents fell 14.35% year-over-year to $8.9 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.9 billion (down 14.35% YoY) and the FY2025 annual result came in at $8.7 billion, down 16.87% from the prior year.
• Cash & Equivalents fell to $8.9 billion in Q4 2025 per BNTX's latest filing, from $11.8 billion in the prior quarter.
• Over five years, Cash & Equivalents peaked at $15.4 billion in Q2 2023 and troughed at $432.8 million in Q3 2021.
• A 5-year average of $8.8 billion and a median of $10.6 billion in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents soared 3027.27% in 2022, then slipped 28.05% in 2024.
• Over 5 years, Cash & Equivalents stood at $1.9 billion in 2021, then surged by 631.05% to $14.2 billion in 2022, then slipped by 11.35% to $12.5 billion in 2023, then decreased by 16.88% to $10.4 billion in 2024, then declined by 14.35% to $8.9 billion in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $8.9 billion, $11.8 billion, and $11.6 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.